Who are LEXIVA (GW433908)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Triple therapy with ritonavir, Riv, continue the PI/r-containing HAART., Tipranavir/Ritonavir, TMC114, LPV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lexiva-gw433908.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

LEXIVA (GW433908) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LEXIVA (GW433908) (LEXIVA (GW433908)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor. Area: Infectious Disease.

phase 3 HIV protease inhibitor HIV-1 protease Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

LEXIVA (GW433908) (LEXIVA (GW433908)) — ViiV Healthcare. Lexiva is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and inhibiting viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LEXIVA (GW433908) TARGET	LEXIVA (GW433908)	ViiV Healthcare	phase 3	HIV protease inhibitor	HIV-1 protease
Triple therapy with ritonavir	Triple therapy with ritonavir	Sociedad Andaluza de Enfermedades Infecciosas	marketed	HIV protease inhibitor	HIV-1 protease
Riv	riv	Pfizer	marketed	Protease Inhibitors	HIV-1 protease
continue the PI/r-containing HAART.	continue the PI/r-containing HAART.	ASST Fatebenefratelli Sacco	phase 3	Protease inhibitor	HIV-1 protease
Tipranavir/Ritonavir	Tipranavir/Ritonavir	Johns Hopkins University	phase 3	Protease inhibitor	HIV-1 protease
TMC114	TMC114	Tibotec Pharmaceuticals, Ireland	phase 3	protease inhibitor	HIV-1 protease
LPV	LPV	Bristol-Myers Squibb	phase 3	HIV protease inhibitor	HIV-1 protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor class)

Bristol-Myers Squibb · 5 drugs in this class
ViiV Healthcare · 3 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Drugs for Neglected Diseases · 2 drugs in this class
Germans Trias i Pujol Hospital · 2 drugs in this class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
DualityBio Inc. · 1 drug in this class
French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
Far East Bio-Tec Co., Ltd · 1 drug in this class
Community Research Initiative of New England · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LEXIVA (GW433908) — Competitive Intelligence Brief. https://druglandscape.com/ci/lexiva-gw433908. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab